# Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

> **NCT05702788** · PHASE2 · WITHDRAWN · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd**

## Conditions studied

- COVID-19
- Pneumonia

## Interventions

- **DRUG:** Jaktinib hydrochloride tablets
- **DRUG:** Jaktinib hydrochloride tablets
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05702788
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-04-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor R\&D Strategy Adjustment
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702788, "Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05702788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*